利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

94 条记录 (耗时 0.021 秒)

    Epinecidin-1 as a vaccine adjuvant for enhancing immune responses
    18.
    发明授权
    Epinecidin-1 as a vaccine adjuvant for enhancing immune responses 有权
    Epinecidin-1作为用于增强免疫应答的疫苗佐剂

    公开(公告)号：US08361483B2

    公开(公告)日：2013-01-29

    申请号：US13070197

    申请日：2011-03-23

    申请人： Jyh-Yih Chen ,  Chang-Jer Wu

    发明人： Jyh-Yih Chen ,  Chang-Jer Wu

    IPC分类号： A61K45/00 ,  A61K39/193 ,  A61K39/12 ,  A61K39/00

    CPC分类号： A61K39/12 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/55516 ,  C12N2770/24134 ,  Y02A50/39

    摘要： A method of enhancing a mammalian immune response to a virus is disclosed. The method comprises administering a composition comprising an effective amount of epinecidin (Epi)-1 and the virus to a mammal, wherein the virus has envelope protein and is infectious to the mammal. A vaccine kit and a method for preventing Japanese encephalitis virus (JEV) infection are also disclosed.

    摘要翻译： 公开了增强对病毒的哺乳动物免疫应答的方法。 该方法包括向哺乳动物施用包含有效量的抗坏血酸（Epi）-1和病毒的组合物，其中所述病毒具有包膜蛋白并且对哺乳动物具有感染性。 还公开了疫苗试剂盒和预防日本脑炎病毒（JEV）感染的方法。

    Compositions and methods for identifying response targets and treating flavivirus infection responses
    19.
    发明授权
    Compositions and methods for identifying response targets and treating flavivirus infection responses 有权
    用于鉴定反应目标和治疗黄病毒感染反应的组合物和方法

    公开(公告)号：US07943134B2

    公开(公告)日：2011-05-17

    申请号：US12079576

    申请日：2008-03-27

    申请人： Shie-Liang Hsieh ,  Chi-Huey Wong ,  Tsui-Ling Hsu ,  Szu-Ting Chen

    发明人： Shie-Liang Hsieh ,  Chi-Huey Wong ,  Tsui-Ling Hsu ,  Szu-Ting Chen

    IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K39/193 ,  A61K45/00 ,  C12N7/00 ,  C07K16/00 ,  C12P21/08 ,  A61K39/285

    CPC分类号： C07K16/2851 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2319/30 ,  G01N2333/18 ,  G01N2333/185 ,  G01N2500/02 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/394

    摘要： Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-α is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-α secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.

    摘要翻译： 鉴定当感染黄病毒如登革热病毒或日本脑炎病毒时诱导血浆渗漏和其它负面影响的细胞受体。 使用本文公开的融合蛋白，确定病原体（例如黄病毒）通过聚糖结合结合的受体。 一旦确定了受体，就可以确定与特定受体结合的作用，其中导致特定症状的受体的靶向可能被阻断病原体与受体结合的试剂所靶向。 因此，在登革热病毒和日本脑炎病毒的情况下，当病原体与DLVR1 / CLEC5A受体结合时，TNF-α被释放。 用单克隆抗体中断DLVR1 / CLEC5A受体降低TNF-α分泌，而不影响负责病毒清除的细胞因子分泌，从而将感染小鼠的存活率从零增加到约50％。